(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Independence from the rat race for Recent college grads: Systems and Tips - 2Scientists may be overestimating the amount of microplastics in the environment – and the culprit is lab gloves
- 3From Loner to Force to be reckoned with: Individual Accounts of Change
- 4Moderna to complete US mRNA manufacturing network with $140 million investment
- 5Twelve injured near Beit Shemesh, reports of shrapnel impact in Eilat as Iran targets Israel
- Language Learning Applications for Voyagers
- Vote In favor of Your Number one Savvy Beds
- Anger as German family business group opens talks with far-right AfD
- Some super-smart dogs can pick up new words just by eavesdropping
- How did I get my own unique set of fingerprints?
- 5 Must-Attempt Fascinating Dishes from Around the World
- What to know about new CDC deputy director who has been critical of COVID vaccines
- Figure out How to Recognize Early Indications of Depressions
- In a first, scientists observe a comet reversing its spin
